MoonLake Immunotherapeutics
MLTXNasdaqCIK 1821586HealthcareFiscal year ends Dec 31
Reports and events: 101 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-3016:15 ET | 8-K | 8.01 Other events | 0001213900-26-105240 |
| 2026-08-1007:46 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001821586-26-000010 |
| 2026-08-1007:15 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-086939 |
| 2026-07-1517:31 ET | 8-K | 8.01 Other events | 0001213900-26-078031 |
| 2026-06-2917:20 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000921895-26-001697 |
| 2026-06-2506:18 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-071721 |
| 2026-06-2207:00 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-070362 |
| 2026-06-0916:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-066821 |
| 2026-06-0106:20 ET | 8-K | 1.01 Entry into a material agreement | 0001213900-26-063125 |
| 2026-05-1108:55 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001821586-26-000007 |
| 2026-05-1107:09 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001821586-26-000005 |
| 2026-04-2116:30 ET | DEF 14A | Proxy statementPeriod 2026-06-04 | 0001140361-26-015916 |
| 2026-04-0216:44 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000921895-26-000894 |
| 2026-02-2506:12 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001821586-26-000002 |
| 2026-02-2306:04 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-018967 |
| 2026-01-0808:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-002344 |
| 2025-11-1017:27 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000921895-25-002943 |
| 2025-11-0517:26 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-25-106723 |
| 2025-11-0507:02 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001821586-25-000022 |
| 2025-11-0507:00 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001821586-25-000021 |
| 2025-09-2907:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-092614 |
| 2025-08-0507:04 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001821586-25-000018 |
| 2025-08-0507:01 ET | 8-K | 2.02 Results of operations | 0001821586-25-000016 |
| 2025-06-0616:30 ET | 8-K | 5.07 Shareholder vote results | 0001213900-25-052140 |
| 2025-05-1216:04 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001821586-25-000011 |
| 2025-05-1216:01 ET | 8-K | 2.02 Results of operations | 0001821586-25-000009 |
| 2025-04-2907:05 ET | 8-K | 7.01 Regulation FD disclosure | 0001213900-25-036363 |
| 2025-04-2216:30 ET | DEF 14A | Proxy statementPeriod 2025-06-05 | 0001140361-25-014923 |
| 2025-04-0307:05 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-028366 |
| 2025-02-2607:13 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001821586-25-000006 |
| 2025-02-2607:09 ET | 8-K | 2.02 Results of operations | 0001821586-25-000004 |
| 2024-12-1816:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001213900-24-110169 |
| 2024-11-0707:05 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001821586-24-000029 |
| 2024-11-0707:03 ET | 8-K | 2.02 Results of operations | 0001821586-24-000028 |
| 2024-10-0818:48 ET | SC 13D/A | Ownership report, active investor, amended | 0000921895-24-002262 |
| 2024-09-1107:30 ET | 8-K | 7.01 Regulation FD disclosure | 0001213900-24-077513 |
| 2024-08-0708:04 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001821586-24-000025 |
| 2024-08-0708:02 ET | 8-K | 2.02 Results of operations | 0001821586-24-000024 |
| 2024-06-1016:40 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-051263 |
| 2024-06-0607:30 ET | 8-K | 5.07 Shareholder vote results | 0001213900-24-050194 |
| 2024-05-0708:02 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001821586-24-000020 |
| 2024-05-0708:01 ET | 8-K | 2.02 Results of operations | 0001821586-24-000019 |
| 2024-05-0707:57 ET | 10-K/A | Annual report, amendedPeriod 2023-12-31 | 0001821586-24-000018 |
| 2024-04-2416:30 ET | DEF 14A | Proxy statementPeriod 2024-06-05 | 0001140361-24-021744 |
| 2024-03-1108:01 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-021233 |
| 2024-03-0516:59 ET | SC 13D/A | Ownership report, active investor, amended | 0000921895-24-000582 |
| 2024-02-2908:05 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001821586-24-000008 |
| 2024-02-2908:03 ET | 8-K | 2.02 Results of operations | 0001821586-24-000007 |
| 2024-02-2609:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-24-016737 |
| 2023-11-1408:05 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001821586-23-000022 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.